FDA Hits Guardian Drug for Lack of Quality Controls, Secure Data Post author:Sam Post published:April 11, 2017 Post category:Drug Industry Daily The FDA cited Guardian Drug Company over quality and data storage issues. Source: Drug Industry Daily You Might Also Like Whistleblower: Mallinckrodt Concealed Vital Information to Drive Acthar Sales April 12, 2018 In Wake of Repeated Rejections, Biogen Abandons Its Flagship AD Drug May 3, 2022 FDA Launching Drug Risk Communications Study for Social Media July 18, 2017
